We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 27, 2022

Discordance Between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA Levels to Determine HER2-Low Status for Breast Cancer

The Journal of Molecular Diagnostics

 

Additional Info

The Journal of Molecular Diagnostics
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer
J Mol Diagn 2022 Jul 01;24(7)775-783, K Xu, J Bayani, E Mallon, GR Pond, T Piper, A Hasenburg, CJ Markopoulos, L Dirix, CM Seynaeve, CJH van de Velde, DW Rea, JMS Bartlett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading